Skip to main content
OpenTrials
Completed

NCT Number: NCT06290895

Artificial Oocyte Activation

Studies reported that calcium signal deficiency or insufficiency during oocyte activation are related with embryo arrest and blastocyst quality. The utilization of Artificial Oocyte Activation (AOA) is safe and does not increase birth defects, cognition, language and motor skills. AOA is the first line of treatment in patients with globozoospermia (round headed spermatozoa). Poor responders in in-vitro fertilization (IVF) cycles represent a major challenge for fertility specialists and comprises about 10-15% of patients undergoing controlled ovarian hyperstimulation. The absence of synergy between the oocyte and sperm leads to a negative impact on oocyte activation. The European Society of Human and REproduction (ESHRE) recommends AOA in cases with failed fertilization/ low fertilization.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Infertility Genital Diseases Ovarian Insufficiency Urogenital Diseases

Age range

18 year–42 year

Sex eligibility

Female

Study type

Observational

Primary location

Clinique Ovo

Montreal, Quebec, H4P 2S4, Canada

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with poor or no blastocyst development in their primary cycle
  • Group 1 - second cycle using AOA following the poor blastocyst development cycle
  • Group 2 - second cycle without AOA following the poor development cycle

Exclusion criteria

  • All cycles who do not have repeat cycles following the poor blastocyst development cycle

Treatment and study plan

women having had a second IVF cycle with AOA

Other

The absence of synergy between the oocyte and sperm leads to a negative impact on oocyte activation. Physiological oocyte activation requires a sperm-derived enzyme called phospholipase C zeta to cause the release of calcium in the form of oscillations from internal storages.

Primary outcomes

  1. Blastocyst rate

    Time frame: 5 days after oocyte fertilization

    Likelihood of an oocyte fertilized to blastocyst stage

Sponsors and collaborators

Lead sponsor

Clinique Ovo

Industry

Registry information

Official study title

The Effect of Artificial Oocyte Activation on Blastocysts Rate in Patients With Low Fertilization Rate

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
Mar 4, 2024
Registry last updated
Mar 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.